518 related articles for article (PubMed ID: 16356494)
1. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
4. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.
Umeoka T; Kawashima T; Kagawa S; Teraishi F; Taki M; Nishizaki M; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Cancer Res; 2004 Sep; 64(17):6259-65. PubMed ID: 15342413
[TBL] [Abstract][Full Text] [Related]
5. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
7. A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus.
Sasaki T; Tazawa H; Hasei J; Osaki S; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Kagawa S; Uno F; Urata Y; Ozaki T; Fujiwara T
Gene Ther; 2013 Jan; 20(1):112-8. PubMed ID: 22241176
[TBL] [Abstract][Full Text] [Related]
8. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
9. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
[TBL] [Abstract][Full Text] [Related]
11. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
Fujiwara T; Tanaka N
Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
[TBL] [Abstract][Full Text] [Related]
12. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
Okegawa T; Sayne JR; Nutahara K; Pong RC; Saboorian H; Kabbani W; Higashihara E; Hsieh JT
J Urol; 2007 Mar; 177(3):1148-56. PubMed ID: 17296436
[TBL] [Abstract][Full Text] [Related]
13. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.
Kitazono M; Goldsmith ME; Aikou T; Bates S; Fojo T
Cancer Res; 2001 Sep; 61(17):6328-30. PubMed ID: 11522619
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
16. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
[TBL] [Abstract][Full Text] [Related]
17. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
Toivonen R; Suominen E; Grenman R; Savontaus M
Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
[TBL] [Abstract][Full Text] [Related]
19. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]